Conventional instruments for cancer diagnosis including magnetic resonance imaging, computed tomography scan, are expensive and require long-waiting time, whilst the outcomes have not approached to the successful early-stage diagnosis yet. Due to the special properties of graphene-based nanocomposites, e.g., good electrical and thermal conductivity, luminescence, and mechanic flexibility, these ultra-thin two-dimensional nanostructures have been extensively used as platforms for detecting biomolecules and cells. Herein, we discuss the development of two types of graphene and graphene oxide-based biosensors: electrochemical and optical, aimed for tumor detection and early diagnosis of cancer. Moreover, we highlight the challenges of their use as biosensors for cancer detection. Efficient surface modification and suitable bio-conjugation of graphene and graphene oxide is discussed, including key role in improvement of the biocompatibility, and improved performance in terms of selectivity and sensitivity towards the early diagnosis of cancer.
Keyphrases
- papillary thyroid
- early stage
- computed tomography
- magnetic resonance imaging
- squamous cell
- high resolution
- lymph node metastasis
- carbon nanotubes
- type diabetes
- induced apoptosis
- multidrug resistant
- magnetic resonance
- ionic liquid
- oxidative stress
- metabolic syndrome
- cell proliferation
- young adults
- radiation therapy
- high speed
- sentinel lymph node
- pet ct
- mass spectrometry
- patient reported outcomes
- cell cycle arrest
- quantum dots
- walled carbon nanotubes
- endoplasmic reticulum stress
- contrast enhanced